Preliminary U.S. BRIUMVI fourth quarter and full year 2024 net product revenue of $103.6 million and $310 million, respectively Full Year 2025 target total global revenue of approximately $540 million, including BRIUMVI U.S. net product revenue of approximately $525 million NEW YORK, Jan.

Presentation scheduled for Monday, January 13, 2025, at 4:30 PM PT NEW YORK , Jan. 09, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss , the Company’s Chairman and Chief Executive Officer, will present at the 43 rd Annual J.P.